Description
DNP (2,4-Dinitrophenol) is the historical prototype of mitochondrial uncouplers. In the 1930s DNP was briefly marketed as an obesity therapeutic, until high incidence of fatal hyperthermia led to market withdrawal. Since then DNP has remained a standard tool in pharmacological research for investigating oxidative phosphorylation.
In research contexts DNP acts as a protonophoric uncoupler: the lipophilic molecule diffuses into the inner mitochondrial membrane and transports protons along their gradient back to the matrix. This bypasses ATP synthase - the energy from nutrient oxidation is released as heat instead of ATP.
The metabolic consequences are dramatic: BMR increases of 40-50% are documented in historical literature, fat loss is very rapid in research settings. The problem is the extremely narrow safety window. Therapeutic and toxic doses lie extremely close together, and toxic action manifests as uncontrollable hyperthermia - body temperature rises faster than the body can dissipate it via sweating.
Known effects even at moderate doses: heavy sweating (especially at night), odor formation (yellowish sweat, urine), tachycardia, dyspnea on exertion, yellow skin discoloration. In studies cataract development and peripheral neuropathies were documented with longer use.
DNP is among the least-recommended metabolism compounds in international research literature. Modern alternatives like BAM15 or GLP-1 agonists offer similar effects with substantially better safety profile.
Pharmacokinetically orally bioavailable with about 36-hour half-life. The long half-life is problematic: accumulation with daily dosing can lead to unexpected level spikes.
You can order DNP as oral tablets with 200mg per tablet, 50 tablets per bottle.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
DNP has the narrowest safety margin of any compound in the entire catalog. The substance was pulled from the market for good reason - the toxicology literature is unambiguous and serious.
Documented in the literature:
- Fatal hyperthermia: the central danger mechanism. The toxic dose sits extremely close to the effective dose. On overdose, body temperature rises faster than the body can shed it - documented cases end in death. There is no antidote.
- Accumulation: the roughly 36-hour half-life means daily dosing can produce unpredictable level spikes - a dose that was fine yesterday can become toxic with today’s accumulation.
- Even at moderate doses: heavy sweating, tachycardia, shortness of breath on exertion, yellow skin discoloration, odor.
- Long-term: cataract development and peripheral neuropathies are documented in studies.
Risk-Tier 3, top end of the scale. DNP ranks among the least-recommended metabolic compounds in the international research literature. Modern alternatives such as BAM15 or GLP-1 agonists offer comparable effects with an incomparably better safety profile. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- 2,4-Dinitrophenol (DNP): A Weight Loss Agent with Significant Acute Toxicity and Risk of Death - Journal of Medical Toxicology 2011, Grundlingh et al: review of the acute toxicity and lethality of DNP, today a standard reference for risk classification.
- International trends in systemic human exposures to 2,4 dinitrophenol reported to poisons centres - Clinical Toxicology 2021, Robert et al: international analysis of 456 documented DNP exposure cases reported to poison centres.
- Mitochondrial Uncoupling Proteins (UCP1-UCP3) and Adenine Nucleotide Translocase (ANT1) Enhance the Protonophoric Action of 2,4-Dinitrophenol in Mitochondria and Planar Bilayer Membranes - Biomolecules 2021, Bertholet et al: mechanism study on the protonophoric uncoupling action of DNP.
- Molecular mechanisms of mitochondrial uncoupling: focus on 2,4-dinitrophenol - European Biophysics Journal 2026, Pohl & Jovanovic: recent review of the molecular mechanisms of mitochondrial uncoupling by DNP.
Stack Notes
- As low and as short as at all possible, if at all. With DNP the effective and the toxic dose sit closer together than with any other compound in the catalog, and the half-life of roughly 36 hours means every dose stacks on top of the previous one. We deliberately do not name figures here.
- Hydration and electrolytes are not an add-on here but part of the risk: DNP-related hyperthermia is life-threatening without adequate fluid.
- Vitamin C is used alongside in practice, because of the documented rise in oxidative stress.
- No heat. Sauna, intense cardio and warm environments raise the hyperthermia risk massively, because they block the exact route by which the body sheds the extra heat.
- BAM15 and the GLP-1 compounds such as Tirzepatide or Retatrutide reach comparable effects in a research context with an incomparably larger safety window. Anyone who has the choice has it there.
